Saturday, November 7, 2020, 8:00 AM - 4:00 PM

In this interdisciplinary conference, an expert, international faculty will present clinical updates in melanoma biology, staging and early disease management. This includes novel approaches to melanoma detection and risk prediction. In addition, exciting advances in the treatment of patients with high-risk and metastatic disease will be discussed with a special emphasis on the multidisciplinary approach to the care of patients with melanoma. Other sessions will feature new data on the role of neoadjuvant and adjuvant therapy, the management of patients with brain metastases and leptomeningeal disease, duration of systemic therapy, changes in the role of surgery and the impact of various prognostic and predictive biomarkers on patient management. Concluding the day will be a session examining the latest approaches to the management of non-melanoma skin cancers. Case presentations and debates will address complex and controversial management issues in patients with high-risk and advanced melanoma and non-melanoma skin cancer.

1. Analyze and apply new insights in the diagnosis and treatment of advanced melanoma.
2. Use appropriate staging modalities to correctly gauge patient risk of recurrence and death and choose the most appropriate patient care strategy.
3. Discuss evolving research and treatment options for patients with disease resistant to IO +/- BRAF/MEK inhibitor therapy.
4. Recognize the value of multidisciplinary evaluation and assessment, in contributing to more effective and expedited patient treatment.
5. Assess new data on molecularly targeted therapies and novel immunotherapy in order to develop integrated treatment plans for patients with various molecular subtypes and stages of disease.
6. Incorporate salvage surgery and targeted radiation in selected patients to enhance long term outcomes.
7. Recognize the changing role in completion lymph node dissection.
8. Describe the new data on choice of combination vs. single agent immunotherapy.
9. Apply new data on adjuvant and neoadjuvant therapy.
10. Recognize new approaches to the management of patients with brain metastases and leptomeningeal disease.
11. Analyze and apply new insights in the treatment of non-melanoma skin cancers.

Registration is now complementary for healthcare providers!

• Physician $150 $0
• Resident and Fellow $50 $0
• Physician Assistant $75 $0
• Nurse Practitioner $75 $0
• Nurse $75 $0
• Allied Health Professional $75 $0
• Industry Professional $325
  
  
  

In support of improving patient care, MedStar Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

 

Credit Designation

This activity was planned by and for the healthcare team, and learners will receive 6.25 Interprofessional Continuing Education (IPCE) credits for learning and change.

Physicians: MedStar Health designates this live activity for a maximum of 6.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Nurses: This activity is approved for 6.25 ANCC contact hour(s). Nurses should claim only the credit commensurate with the extent of their participation in the activity.

AMA PRA Category 1 Credits™ Physician (6.75 hours), Nurse - ANCC (6.75 hours), Non-Physician Member of the Healthcare Team (6.75 hours), IPCE (6.75 hours)